Dr. Mª José Terol Casterá

Principal Investigator
Research Group on Lymphoproliferative Disorders

Presentation

Principal
Investigator
Dr. Mª José Terol Casterá

maria.jose.terol@uv.es  

Publications
Feasibility and outcomes after dose reduction of immunochemotherapy in young adults with Burkitt lymphoma and leukemia: results of the BURKIMAB14 trial. Ribera J, Morgades M, Garcia-Calduch O, Sirvent M, Buendia B, Cervera M, Luzardo H, Hernandez-Rivas J, Sitges M, Garcia-Cadenas I, Abrisqueta P, Montesinos P, Bastos-Oreiro M, De Llano M, Bravo P, Torrent A, Herrera P, Garcia-Guinon A, Vall-Llovera F, Serrano J, Terol M, Bergua J, Garcia-Noblejas A, Barrenetxea C, Llorente L, Garcia-Belmonte D, Gimeno E, Cladera A, Mercadal S, Sancho J. Haematologica. 2024 Feb 1;109(2):543-552. doi: 10.3324/haematol.2023.283342. PMID: 37560813

Accuracy and prognostic impact of FDG PET/CT and biopsy in bone marrow assessment of follicular lymphoma at diagnosis: a nation-wide cohort study. Rodenas-Quinonero I, Chen-Liang T, Martin-Santos T, Salar A, Fernandez-Gonzalez M, Celades C, Navarro J, Martinez-Garcia A, Andreu R, Balaguer A, Garcia-Sancho A, Baile M, Lopez-Jimenez J, Marquet-Palomanes J, Teruel A, Terol M, Benet C, Frutos L, Navarro J, Una J, Suarez M, Cortes M, Contreras J, Ruiz C, Tamayo P, Mucientes J, Sopena-Novales P, Reguilon-Gallego L, Sanchez-Blanco J, Perez-Ceballos E, Jerez A, Ortuno F. Cancer Medicine. 2023 Mar;12(6):6536-6546. doi: 10.1002/cam4.5424. PMID: 36373169

Correction: Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY. Mansouri L, Thorvaldsdottir B, Sutton LA, Karakatsoulis G, Meggendorfer M, Parker H, Nadeu F, Brieghel C, Laidou S, Moia R, Rossi D, Catherwood M, Kotaskova J, Delgado J, Rodriguez-Vicente AE, Benito R, Rigolin GM, Bonfiglio S, Scarfo L, Mattsson M, Davis Z, Gogia A, Rani L, Baliakas P, Foroughi-Asl H, Jylha C, Skaftason A, Rapado I, Miras F, Martinez-Lopez J, de la Serna J, Hernandez Rivas JM, Thornton P, Larrayoz MJ, Calasanz MJ, Fesus V, Matrai Z, Bodor C, Smedby KE, Espinet B, Puiggros A, Gupta R, Bullinger L, Bosch F, Tazon-Vega B, Baran-Marszak F, Oscier D, Nguyen-Khac F, Zenz T, Terol MJ, Cuneo A, Hernandez-Sanchez M, Pospisilova S, Mills K, Gaidano G, Niemann CU, Campo E, Strefford JC, Ghia P, Stamatopoulos K, Rosenquist R. Leukemia. 2023 Feb;37(2):504. doi: 10.1038/s41375-023-01813-3. PMID: 36635392

Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY. Mansouri L, Thorvaldsdottir B, Sutton LA, Karakatsoulis G, Meggendorfer M, Parker H, Nadeu F, Brieghel C, Laidou S, Moia R, Rossi D, Catherwood M, Kotaskova J, Delgado J, Rodríguez-Vicente AE, Benito R, Rigolin GM, Bonfiglio S, Scarfo L, Mattsson M, Davis Z, Gogia A, Rani L, Baliakas P, Foroughi-Asl H, Jylhä C, Skaftason A, Rapado I, Miras F, Martinez-Lopez J, de la Serna J, Rivas JMH, Thornton P, Larráyoz MJ, Calasanz MJ, Fésüs V, Mátrai Z, Bödör C, Smedby KE, Espinet B, Puiggros A, Gupta R, Bullinger L, Bosch F, Tazón-Vega B, Baran-Marszak F, Oscier D, N’Guyen-Khac F, Zenz T, Terol MJ, Cuneo A, Hernández-Sánchez M, Pospisilova S, Mills K, Gaidano G, Niemann CU, Campo E, Strefford JC, Ghia P, Stamatopoulos K, Rosenquist R. Leukemia. 2023 Feb;37(2):339-347. doi: 10.1038/s41375-022-01802-y. PMID: 36566271

IGLV3-21R110 mutation has prognostic value in patients with treatment-naive chronic lymphocytic leukemia. Syrykh C, Pons-Brun B, Russiñol N, Playa-Albinyana H, Baumann T, Duran-Ferrer M, Kulis M, Carbó-Meix A, Mozas P, Alcoceba M, González M, Navarro-Bailón A, Colado E, Payer ÁR, Aymerich M, Terol MJ, Lu J, Knisbacher BA, Hahn CK, Ruiz-Gaspà S, Enjuanes A, Wu CJ, Getz G, Zenz T, López-Guillermo A, Martín-Subero JI, Colomer D, Delgado J, Campo E, Nadeu F. Blood Advances. 2023 Dec 12;7(23):7384-7391. doi: 10.1182/bloodadvances.2023010132. PMID: 37505099

Immunobiology of cytomegalovirus infection in patients with haematological malignancies undergoing treatment with small molecule inhibitors. Solano De la Asuncion C, Gimenez E, Hernandez-Boluda JC, Terol MJ, Albert E, Lopez-Jimenez J, Garcia-Gutierrez V, Andreu R, Garcia D, Fox ML, Remigia MJ, Amat P, Solano C, Navarro D. British Journal of Haematology. 2023 Mar;200(6):e58-e61. doi: 10.1111/bjh.18655. PMID: 36652997

Impact of SCHOLAR-1 criteria on CAR-T cell therapy efficacy in aggressive B lymphoma. A real-world GELTAMO/GETH study. Oreiro M, Gutierrez A, Iacoboni G, Corral L, Reguera J, Abrisqueta P, Delgado J, Terol M, Hernani R, Martinez N, Ortiz V, Bailen R, Gomez-Centurion I, Caballero A, Sanz J, Dominguez L, Hugo L, Musseti A, Ubieto A, Sancho J, Sureda A, Perez A, Barba P, Kwon M, Garcia-Sancho A. Transplantation And Cellular Therapy. 2023 Aug 31;S2666-6367(23)01508-7. doi: 10.1016/j.jtct.2023.08.026. PMID: 37659694

Low-risk HPLLs/ABC score patients with splenic marginal zone lymphoma can be safely managed without treatment: results from a prospective Spanish study. Muntanola A, Villalobos M, Gonzalez-Villambrosia S, Rodriguez-Salazar M, Jimenez-Ubieto A, Bastidas-Mora G, Cordoba R, Infante M, Vidal M, Diaz F, Baile M, Bastos-Oreiro M, Panizo C, Sancho J, Navarro B, Garcia T, Escoda L, Abrisqueta P, Terol M, de Campo R, Mozas P, Lopez-Guillermo A, Salar A, Montalban C. British Journal of Haematology. 2023 Aug;202(4):776-784. doi: 10.1111/bjh.18912. PMID: 37386877

Obinutuzumab plus bendamustine for relapsed/refractory chronic lymphocytic leukemia and predictive and prognostic impact of genetic alterations: the phase II GABRIELL study. Bravo J, Tello P, Garcia E, Herranz E, Payer A, Castera M, Champ D, Perez A, Gironella M, Zarzoso M, Fores R, Delgado J, Garcia-Marco J, GABRIELL Study Grp Investigators. Leukemia & Lymphoma. 2023 May;64(5):913-926. doi: 10.1080/10428194.2023.2216327. PMID: 37255002

SARS-CoV-2-reactive antibody waning, booster effect and breakthrough SARS-CoV-2 infection in hematopoietic stem cell transplant and cell therapy recipients at one year after vaccination. Pinana J, Martino R, Vazquez L, Lopez-Corral L, Perez A, Chorao P, Avendano Pita A, Pascual M, Sanchez Salinas A, Sanz Linares G, Olave M, Arroyo I, Tormo M, Villalon L, Conesa Garcia V, Gago B, Terol M, Villalba M, Garcia Gutierrez V, Cabero A, Hernandez Rivas J, Ferrer E, Garcia Cadenas I, Teruel A, Navarro D, Cedillo A, Sureda A, Solano C. Bone Marrow Transplantation. 2023 Feb 28;1-14. doi: 10.1038/s41409-023-01946-0. PMID: 36854892

Torque Teno Virus plasma DNA load: a novel prognostic biomarker in CAR-T therapy. Benzaquén A, Giménez E, Iacoboni G, Guerreiro M, Hernani R, Albert E, Carpio C, Balaguer A, Pérez A, S de la Asunción C, Sánchez-Salinas MA, Chorão P, Piñana JL, Beas F, Montoro J, Hernández-Boluda JC, Facal A, Ferrer B, Villalba M, Amat P, Goméz MD, Campos D, Terol MJ, Sanz J, Barba P, Navarro D, Solano C. Bone Marrow Transplantation. 2023 Nov 2. doi: 10.1038/s41409-023-02114-0. PMID: 37919456

A randomized phase II study comparing consolidation with a single dose of 90Y ibritumomab tiuxetan vs. maintenance with rituximab for two years in patients with newly diagnosed follicular lymphoma responding to R-CHOP. Long-term follow-up results. Lopez-Guillermo A, Canales M, Dlouhy I, Mercadal S, Briones J, Garcia-Sancho A, Sancho J, Moraleda J, Terol M, Salar A, Palomera L, Gardella S, Jarque I, Ferrer S, Bargay J, Lopez A, Panizo C, Muntanola A, Montalban C, Conde E, Hernandez M, Soler A, Marco J, Deben G, Marin J, Tomas J, PETHEMA GELTAMO GELCAB Spanish. Leukemia & Lymphoma. 2022 Jan;63(1):93-100. doi: 10.1080/10428194.2021.1971216. PMID: 34459702

Applicability of probabilistic graphical models for early detection of SARS-CoV-2 reactive antibodies after SARS-CoV-2 vaccination in hematological patients. Pinana J, Rodriguez-Belenguer P, Caballero D, Martino R, Lopez-Corral L, Terol M, Vazquez L, Calabuig M, Sanz-Linares G, Marin-Jimenez F, Alonso C, Montoro J, Ferrer E, Facal A, Pascual M, Rodriguez-Fernandez A, Olave M, Cascales-Hernandez A, Gago B, Hernandez-Rivas J, Villalon L, Corona M, Roldan-Perez A, Ribes-Amoros J, Gonzalez-Santillana C, Garcia-Sanz R, Navarro D, Serrano-Lopez A, Cedillo A, Soria-Olivas E, Sureda A, Solano C. Annals of Hematology. 2022 Sep;101(9):2053-2067. doi: 10.1007/s00277-022-04906-8. PMID: 35780254

Best treatment option for patients with refractory aggressive b-cell lymphoma in the car-t cell era: real-world evidence from GELTAMO/GETH Spanish Groups. Bastos-Oreiro M, Gutierrez A, Reguera J, Iacoboni G, Lopez-Corral L, Terol M, Ortiz-Maldonado V, Sanz J, Guerra-Dominguez L, Bailen R, Mussetti A, Abrisqueta P, Hernani R, Luzardo H, Sancho J, Delgado-Serrano J, Salar A, Grande C, Bento L, de Villambrosia S, Garcia-Belmonte D, Sureda A, Perez-Martinez A, Barba P, Kwon M, Garcia-Sancho A. Frontiers in Immunology. 2022 Jul 12;13:855730. doi: 10.3389/fimmu.2022.855730. PMID: 35911769

Genetic and phenotypic characterization of HIV-associated aggressive B-cell non-Hodgkin lymphomas, that do not occur specifically in this population: diagnostic and prognostic implications. Baptista MJ, Tapia G, Munoz-Marmol AM, Muncunill J, Garcia O, Montoto S, Gribben JG, Calaminici M, Martinez A, Veloza L, Martinez-Trillos A, Aldamiz T, Menarguez J, Terol MJ, Ferrandez A, Alcoceba M, Briones J, Gonzalez-Barca E, Climent F, Muntanola A, Moraleda JM, Provencio M, Abrisqueta P, Abella E, Colomo L, Garcia-Ballesteros C, Garcia-Caro M, Sancho JM, Ribera JM, Mate JL, Navarro JT. Histopathology. 2022 Dec;81(6):826-840. doi: 10.1111/his.14798. PMID: 36109172

Ibrutinib in combination with rituximab for indolent clinical forms of mantle cell lymphoma (IMCL-2015): a multicenter, open-label, single-arm, Phase II Trial. Giné E, de la Cruz F, Jiménez Ubieto A, López Jimenez J, Martín García-Sancho A, Terol MJ, González Barca E, Casanova M, de la Fuente A, Marín-Niebla A, Muntañola A, González-López TJ, Aymerich M, Setoain X, Cortés-Romera M, Rotger A, Rodríguez S, Medina Herrera A, García Sanz R, Nadeu F, Beà S, Campo E, López-Guillermo A. Journal of Clinical Oncology. 2022 Apr 10;40(11):1196-1205. doi: 10.1200/JCO.21.02321. PMID: 35030036

Multi-body-site colonization screening cultures for predicting multi-drug resistant Gram-negative and Gram-positive bacteremia in hematological patients. Torres I, Huntley D, Tormo M, Calabuig M, Hernandez-Boluda J, Terol M, Carretero C, de Michelena P, Perez A, Pinana J, Colomina J, Solano C, Navarro D. BMC Infectious Diseases. 2022 Feb 21;22(1):172. doi: 10.1186/s12879-022-07154-3. PMID: 35189833

Real world data of anticoagulant treatment in non-valvular atrial fibrillation across renal function status. Calderon J, Martinez F, Fernandez A, Sauri I, Diaz J, Uso R, Trillo J, Redon J, Forner M. Scientific reports. 2022 Apr 12;12(1):6123. doi: 10.1038/s41598-022-10164-5. PMID: 35414001

Validation of the Burkitt Lymphoma International Prognostic Index in patients treated with two prospective chemoimmunotherapy trials in Spain. Ribera J, Garcia O, Buendia-Urena B, Terol M, Vicent A, Vall-Llovera F, Bergua J, Garcia-Cadenas I, Esteve J, Ribera J, Acuna-Cruz E, Herrera P, Hernandez-Rivas J, Abrisqueta P, Gonzalez-Campos J, Rodriguez C, Bastos-Oreiro M, Genesca E, Caminos N, de Llano M, Cladera A, Sancho J. Leukemia & Lymphoma. 2022 Aug;63(8):1993-1996. doi: 10.1080/10428194.2022.2053531. PMID: 35343365

Building a network of TP53 and IGHV testing reference centers across Spain: the Red53 initiative. Bosch F, Navarro B, Crespo M, Alcoceba M, Sanchez J, Tazon B, Serrano A, Alvarez M, Serrano L, Alonso-Torres P, Villanueva M, Loriente C, Abrisqueta P, Peiro M, Garcia-Marco J, Gonzalez M, Terol M. Annals of Hematology. 2021 Mar;100(3):825-830. doi: 10.1007/s00277-020-04331-9. PMID: 33409623

CAR-T therapy in solid transplant recipients with post-transplant lymphoproliferative disease: case report and literature review. Hernani R, Sancho A, Amat P, Hernandez-Boluda J, Perez A, Pinana J, Carretero C, Goterris R, Gomez M, Saus A, Ferrer B, Teruel A, Terol M, Solano C. Current Research in Translational Medicine. 2021 Jul 22;69(4):103304. doi: 10.1016/j.retram.2021.103304. PMID: 34303899

Cytomegalovirus-specific T-cell immunity and DNAemia in patients with chronic lymphocytic leukaemia undergoing treatment with ibrutinib. De la Asuncion C, Terol M, Saus A, Olea B, Gimenez E, Albert E, Lopez-Jimenez J, Andreu R, Garcia D, Fox L, Remigia M, Amat P, Solano C, Navarro D. British Journal of Haematology. 2021 Nov;195(4):637-641. doi: 10.1111/bjh.17732. PMID: 34402042

Immunological and genetic kinetics from diagnosis to clinical progression in chronic lymphocytic leukemia. Jimenez I, Tazon-Vega B, Abrisqueta P, Nieto JC, Bobillo S, Palacio-Garcia C, Carabia J, Valdes-Mas R, Munuera M, Puigdefabregas L, Parra G, Esteve-Codina A, Franco-Jarava C, Iacoboni G, Terol MJ, Garcia-Marco JA, Crespo M, Bosch F. Biomarker Research. 2021 May 20;9(1):37. doi: 10.1186/s40364-021-00290-z. PMID: 34016160

Real-World Characteristics and Outcome of Patients Treated With Single-Agent Ibrutinib for Chronic Lymphocytic Leukemia in Spain (IBRORS-LLC Study). Abrisqueta P, Loscertales J, Terol MJ, Ramirez Payer A, Ortiz M, Perez I, Cuellar-Garcia C, Fernandez de la Mata M, Rodriguez A, Lario A, Delgado J, Godoy A, Arguinano Perez JM, Berruezo MJ, Oliveira A, Hernandez-Rivas JA, Garcia Malo MD, Medina A, Garcia Martin P, Osorio S, Baltasar P, Fernandez-Zarzoso M, Marco F, Vidal Mancenido MJ, Smucler Simonovich A, Lopez Rubio M, Jarque I, Suarez A, Fernandez Alvarez R, Lancharro Anchel A, Rios E, Losada Castillo MC, Perez Persona E, Garcia Munoz R, Ramos R, Yanez L, Bello JL, Loriente C, Acha D, Villanueva M. Clinical Lymphoma, Myeloma & Leukemia. 2021 Dec;21(12):e985-e999. doi: 10.1016/j.clml.2021.07.022. PMID: 34511320

Restoration of the immune function as a complementary strategy to treat Chronic Lymphocytic Leukemia effectively. Moreno C, Munoz C, Terol MJ, Hernandez-Rivas JA, Villanueva M. Journal of Experimental & Clinical Cancer Research. 2021 Oct 15;40(1):321. doi: 10.1186/s13046-021-02115-1. PMID: 34654437

Projects
Reference: PMP21/00015
Title: Medicina de precisión genómica en neoplasias linfoides (PREGENLINF)
Funding body: Instituto de Salud Carlos III – Cofinanciado FEDER
Principal Investigator: Elías Campo Güerri
Duration: 2022 – 2025
Total budget: 3.063.060
+ Info
Title: La leucemia linfática crónica: evolución clonal y su monitorización molecular
Doctoral candidate: Serrano Alcalá, Alicia
Director(s): Navarro Cubells, Blanca; Terol Casterá Mª José; Chaves Martínez, Felipe Javier
Date of the defense: 30/05/2023
University: University de Valencia

Title: Development of bioinformatics tools for the characterization of B cell neoplasms
Doctoral candidate: Fuentes Trillo, Azahara Maria
Director(s): Chaves Martínez, Felipe Javier; Navarro Cubells, Blanca; Terol Casterá, María José
Date of the defense: 10/03/2023
University: Universitat de València